Related Experiment Video

Updated: Aug 14, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction

Lars Bjerrum1, Morten Andersen, Jesper Hallas

  • 1Research Unit of General Practice, University of Southern Denmark, J.B. Winslows Vej 9, 5000, Odense C, Denmark. lbjerrum@health.sdu.dk

European Journal of Clinical Pharmacology
|December 7, 2005
PubMed

Insights

Past use of antibiotics targeting Chlamydia pneumoniae (CP) showed no association with a reduced risk of myocardial infarction (MI). This study did not support the hypothesis that CP-active antibiotics offer primary prevention benefits for MI.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Chlamydia pneumoniae (CP) is implicated in the etiology of myocardial infarction (MI).
  • Antibiotic use for secondary MI prevention lacks proven benefit, but evidence for primary prevention is inconsistent.
  • The role of CP-active antibiotics in MI primary prevention requires further investigation.

Purpose of the Study:

  • To investigate the association between past antibiotic use targeting CP and the risk of developing MI.
  • To evaluate if macrolides, tetracyclines, or quinolones are associated with decreased MI risk.
  • To explore potential protective effects in specific patient subgroups.

Main Methods:

  • A population-based case-control study involving 4166 MI patients and 16,664 controls.
  • Matched analysis controlling for confounders including age, sex, diabetes, and prior MI.
  • Analysis of antibiotic exposure, specifically CP-active agents (macrolides, tetracyclines, quinolones) versus non-active agents (penicillins).

Main Results:

  • No significant association was found between MI risk and prior exposure to macrolides, tetracyclines, or quinolones (ORs approximately 1.0).
  • Combined use of these CP-active antibiotics also showed no association with reduced MI risk.
  • No protective effect was observed in subgroups based on antibiotic dosage, exposure timing, or patient risk factors.

Conclusions:

  • The study findings do not support the hypothesis that antibiotics active against CP reduce the risk of myocardial infarction.
  • Current evidence does not indicate a role for CP-active antibiotics in the primary prevention of MI.
Abstract

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic of...